The Conversation (0)
- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Chart
Detailed Quote
3SBio is one of the largest and most established biotech drugmakers in China. Approximately 90 percent of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
Featured Articles and Interviews
Oct 23, 2025
Biotech and Pharma Market Update: Q3 2025 in Review
Press Releases
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.